Decoy Therapeutics Inc. Common Stock
DCOY
Closed
$5.75
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Decoy Therapeutics, Inc. operates as a preclinical-stage biotechnology company. The company is headquartered in Houston, Texas and currently employs 11 full-time employees. The company went IPO on 2015-01-29. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.
Key stats
Open
$5.59
Volume
18.87K
Market cap
$3.11M
Prev. close
$5.84
Impl / hst vl
-
Open interest
$0.00
$5.43
Day’s Range
$5.90
$0.53
52W Range
$13.51
Valuation
55
Valuation score
Fairly Valued
P/E
-
P/S
-
P/B
0.80
Current ratio
1.84
Debt / Equity
-2.02
ROE
-258.50%
Gross margin
-
Income growth
-75.22%
FCF growth
154.23
Analysts estimates
Consensus rating
Hold
The average rating from top 3 analysts indicates that stock may significantly underperform the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$30.60
The top 3 analysts forecasts that 12-month price may increase by 432.17%, with a low of $30.30 and a high of $31.50
$30.30
Low
$30.60
Avg
$31.50
High
Current price
Earnings
Q1 ‘26 revenue
$0.00
Q1 ‘26 net income
-$2.22M
Revenue
Net income
Previous EPS
-Estimate EPS
$0.00
Actual EPS
Estimate EPS
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply